NewslettersMuscle Cell NewsBenitec Biopharma Enrolls First OPMD Subject into the Clinical Development ProgramBy Jamie Kang - January 23, 20230178Benitec Biopharma Inc. announced the enrollment of the first oculopharyngeal muscular dystrophy (OPMD) patient into the OPMD natural history phase of the BB-301 clinical development program.[Benitech Biopharma, Inc.]Press Release